Search Results - "Falcón, Silvia"

Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial by AJANI, Jaffer A, RODRIGUEZ, Wuilbert, BODOKY, Gyorgy, MOISEYENKO, Vladimir, LICHINITSER, Mikhail, GORBUNOVA, Vera, VYNNYCHENKO, Ihor, GARIN, August, LANG, Istvan, FALCON, Silvia

“…Patients with advanced gastric or gastroesophageal adenocarcinoma need more efficacious and safer treatments than established today. S-1, a contemporary oral…”
Get full text

Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial by STERNBERG, Cora N, PETRYLAK, Daniel P, BODROGI, Istvan, HARPER, Peter, WIRTH, Manfred, BERRY, William, PETRONE, Michael E, MCKEARN, Thomas J, NOURSALEHI, Mojtaba, GEORGE, Martine, ROZENCWEIG, Marcel, SARTOR, Oliver, WITJES, J. Alfred, DEMKOW, Tomasz, FERRERO, Jean-Marc, EYMARD, Jean-Christophe, FALCON, Silvia, CALABRO, Fabio, JAMES, Nicholas

“…This multinational, double-blind, randomized, placebo-controlled, phase III trial assessed the efficacy and tolerability of the oral platinum analog…”
Get full text

Adaptation of international coronavirus disease 2019 and breast cancer guidelines to local context by Valencia, Guillermo Arturo, Neciosup, Silvia, Gómez, Henry L, Benites, Maria Del Pilar, Falcón, Silvia, Moron, David, Veliz, Karin, Maldonado, Mike, Auqui, Rodrigo

“…The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (a novel coronavirus), which was first identified…”
Get full text

Practice-Changing Use of the 21-Gene Test for the Management of Patients With Early-Stage Breast Cancer in Latin America by Gomez, Henry L, Bargallo-Rocha, Juan E, Billinghurst, Roberto J, Núñez De Pierro, Aníbal R, Coló, Federico A, Gil, Lisandro L B, Allemand, Carola, McLean, Ignacio L, Lema-Medina, Mauricio, Herazo-Maya, Fernando, Terrier, Francisco J, Cwilich, Raquel G, Leon, Mauricio, Falcon, Silvia G, Castaño, Roberto E, Oliveira, Sergio C, Jakubowski, Debbie M, Chao, Calvin

“…We present a physician survey of the impact of 21-gene Breast Recurrence Score test results on treatment decisions in clinical practice in Latin America. This…”
Get full text

Treatment of Advanced Hormone-Sensitive Breast Cancer in Postmenopausal Women With Exemestane Alone or in Combination With Celecoxib by DIRIX, Luc Yves, IGNACIO, Jorge, ABBATTISTA, Antonello, LOBELLE, Jean-Pierre, NAG, Shona, BAPSY, Poonamally, GOMEZ, Henry, RAGHUNADHARAO, Digumarti, PARIDAENS, Robert, JONES, Stephen, FALCON, Silvia, CARPENTIERI, Marina

“…Preclinical data showed that the combination of exemestane and celecoxib has synergistic effects. Therefore, a study was undertaken to explore the efficacy and…”
Get full text

PO88 - REAL WORLD DATA OF CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN A EUROPEAN AND LATIN-AMERICAN LUMINAL ADVANCED BREAST CANCER POPULATION. ANALYSIS OF TWO CENTERS by Samamé Pérez-Vargas, Juan Carlos, Cudós, Ariadna Gasol, Rivera Francia, Victor Mauricio, Garrido-Lecca, Alejandro León, Lizaraso, Silvia Falcón, Murillo, Serafin Morales

Get full text

REAL WORLD DATA OF CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN A EUROPEAN AND LATIN-AMERICAN LUMINAL ADVANCED BREAST CANCER POPULATION. ANALYSIS OF TWO CENTERS by Samamé Pérez-Vargas, Juan Carlos, Cudós, Ariadna Gasol, Rivera Francia, Victor Mauricio, Garrido-Lecca, Alejandro León, Lizaraso, Silvia Falcón, Murillo, Serafin Morales

Get full text

Predictors of response and surgical approach after neoadjuvant chemotherapy in receptor-positive/HER2-negative stage II-III breast cancer patients treated in two private cancer care centers in Lima, Peru: Real-world data by Aldecoa-Bedoya, Franklin, Aldecoa-Falcon, Sebastian, Falcon, Silvia Gabriela

“…e12659 Background: The role of neoadjuvant chemotherapy (NAC) in hormone receptor-positive HER2-negative breast cancer (BC) is controversial, its main benefit…”
Get full text

Clinical Outcomes in Adult T Leukemia/Lymphoma: Report of 55 Cases from Peru by Beltrán-Gárate, Brady E., Carrasco-Yalan, Antonio A., Lopéz-Odría, Olga M., Riva-Gonzales, Luis, Ríos, Hugo, Chumpitáz-Anchiraico, Gloria, Falcón-Lisarazo, Silvia, Navarro-M, Juan, de Mendoza, Fernando Hurtado, Castillo-Aguirre, Jorge

“…Adult T -cell leukaemia/lymphoma (ATL) is an aggressive disease associated with human T-cell lymphotropic virus type-I (HTLV-I) with heterogeneous clinical…”
Get full text

Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma by Motzer, Robert J, Barrios, Carlos H, Kim, Tae Min, Falcon, Silvia, Cosgriff, Thomas, Harker, W Graydon, Srimuninnimit, Vichien, Pittman, Ken, Sabbatini, Roberto, Rha, Sun Young, Flaig, Thomas W, Page, Ray, Bavbek, Sevil, Beck, J Thaddeus, Patel, Poulam, Cheung, Foon-Yiu, Yadav, Sunil, Schiff, Edward M, Wang, Xufang, Niolat, Julie, Sellami, Dalila, Anak, Oezlem, Knox, Jennifer J

“…A multicenter, randomized phase II trial, RECORD-3, was conducted to compare first-line everolimus followed by sunitinib at progression with the standard…”
Get full text

HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuvant trastuzumab after 2 years of treatment-free follow-up by Jackisch, Christian, Hegg, Roberto, Stroyakovskiy, Daniil, Ahn, Jin-Seok, Melichar, Bohuslav, Chen, Shin-Cheh, Kim, Sung-Bae, Lichinitser, Mikhail, Starosławska, Elżbieta, Kunz, Georg, Falcon, Silvia, Chen, Shou-Tung, Crepelle-Fléchais, Aulde, Heinzmann, Dominik, Shing, Mona, Pivot, Xavier

“…Abstract Background In the phase III, open-label, randomised HannaH study, fixed-dose neoadjuvant–adjuvant subcutaneous trastuzumab for human epidermal growth…”
Get full text

Practice-changing use of the 21-gene oncotype DX breast recurrence score test in Latin American hospitals by Gomez, Henry Leonidas, Bargallo-Rocha, Juan Enrique, Billinghurst, Roberto Jorge, Núñez de Pierro, Aníbal Roberto, Coló, Federico Andrés, Benitez Gil, Lisandro Luis, Allemand, Carola, McLean, Ignacio Leonardo, Lema-Medina, Mauricio, Herazo-Maya, Fernando, Terrier, Francisco Jose, Gerson Cwilich, Raquel, León Rivera, Mauricio, Falcon, Silvia Gabriela, Castaño, Roberto Eduardo, Oliveira, Sergio Cordeiro, Jakubowski, Debbie M, Chao, Calvin Y.

“…Abstract only e12539 Background: The 21-gene test is clinically validated to predict chemotherapy (CT) benefit in node-negative (N0) and node-positive (up to 3…”
Get full text

Neoadjuvant pertuzumab in non‑metastatic HER2‑positive breast tumors: Multicentric study in Peru (NeoHer) by Falcon, Silvia, Riva, Luis, Flores, Christina, Vera, Delphis, Pinto, Joseph A, Gomez, Henry L

“…Several clinical trials have demonstrated the benefit of adding pertuzumab to trastuzumab plus neoadjuvant chemotherapy in the treatment of human epidermal…”
Get full text

Clinical validation of 2 morbidity groups in the primary care setting by Clèries, Montse, Monterde, David, Vela, Emili, Guarga, Àlex, García Eroles, Luis, Pérez Sust, Pol

“…Adjusted Morbidity Groups (GMAs) and the Clinical Risk Groups (CRGs) are population morbidity based stratification tools which classify patients into mutually…”
Get full text

Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC) by Motzer, Robert John, Barrios, Carlos H., Kim, Tae Min, Falcon, Silvia, Cosgriff, Thomas, Harker, W. Graydon, Pittman, Kenneth B., Sabbatini, Roberto, Rha, Sun Young, Flaig, Thomas W., Page, Ray D., Bavbek, Sevil E., Beck, J. Thaddeus, Patel, Poulam M, Schiff, Edward, Vaury, Alexandra, Niolat, Julie, Gogov, Sven, Anak, Ozlem, Knox, Jennifer

“…Abstract only 4504 Background: Sequential SUN (tyrosine kinase inhibitor, TKI) until progression of disease (PD) followed by EVE (mTOR inhibitor) is standard…”
Get full text

Abstract PO2-05-06: Palbociclib in advanced hormone receptor positive breast cancer: A real world study in South America by SÁNCHEZ, Cesar, Samtani, Suraj, Gómez, Henry, Falcon-Lizaraso, Silvia, Muñoz, René, Soria, Tannia

“…BACKGROUND: First-line combined endocrine therapy is the standard of care for hormone receptor-positive (HR+) human epidermal growth factor receptor 2…”
Get full text

Validación clínica de 2 agrupadores de morbilidad en el ámbito de atención primaria by Clèries, Montse, Monterde, David, Vela, Emili, Guarga, Àlex, García Eroles, Luis, Pérez Sust, Pol

“…Resumen Introducción Los grupos de morbilidad ajustados (GMA) y los clinical risk groups (CRG) son herramientas de estratificación poblacional basada en la…”
Get full text

Abstract P4-06-12: Decision of Neoadjuvant Therapy in Younger vs. Older Breast Cancer Patients: A Real-World Data Analysis by Alanya, Enrique, Falcon-Lizaraso, Silvia, Aldecoa-Falcon, Sebastian, Aldecoa-Bedoya, Franklin

“…Background: The incidence of breast cancer among younger patients (age ≤ 40) is higher in Latin America than in other regions. The multidisciplinary approach…”
Get full text

A Multicenter, Single-Arm Phase II Study of Pemetrexed Plus Doxorubicin Administered Every 21 Days in Patients With Advanced Breast Cancer by Martin, Miguel, Blasinska-Morawiec, Maria, Salas, J. Fernando, Falcon, Silvia, Rolski, Janusz, Ferrari, Bruno L, Gulyas, Stephen, Liu, Yushan, Benhadji, Karim A

“…Abstract Background Doxorubicin and pemetrexed have both shown single-agent activity in breast cancer. Preclinical and clinical evidence indicates that a…”
Get full text

A phase II study of neoadjuvant gemcitabine plus doxorubicin in stage IIIB breast cancer: a preliminary report by Gomez, H, Kahatt, C, Falcon, S, Santillana, S, de Mendoza, F H, Valdivia, S, Vallejos, C, Otero, J, Pen, D L

“…The purpose of this ongoing study is to determine the response and safety of a combination of gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN)…”
Get more information